← Issue №14/ week of Oct 4, 2026/Hepatology

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology retrospective · n=113 · Sep 28, 2026 · J Gastro Hep · IF 3.5

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage.

New evidencehepatocellular carcinoma
Clinical takeawayConsider atezolizumab plus bevacizumab for BCLC-B2 HCC patients, especially those with high tumor burden (tumor number plus size ≥11), as it showed survival benefit in this retrospective analysis. Note that these findings are exploratory and associative, not causal.
What it foundAtezolizumab plus bevacizumab was associated with a survival benefit (OR 3.77, p=0.0065) exceeding model predictions in BCLC-B2 HCC, particularly in high tumor burden (tumor number plus size ≥11), based on retrospective data.
ContextChallenges the standard of care (transarterial chemoembolization) for BCLC-B2 HCC, suggesting systemic therapy may offer superior survival in selected patients based on retrospective data.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Ouchi K … Masamune A · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues